Trial Profile

A retrospective, multicenter study assessing the efficacy and safety ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

11 Feb 2023 Results assessing sequencing strategies of ramucirumab and docetaxel following prior treatments, including immune checkpoint inhibitor (ICI), cytotoxic agent alone, bevacizumab, and tyrosine kinase inhibitor (TKI), published in the European Journal of Clinical Pharmacology.
20 Jan 2022 New trial record
13 Jan 2022 Primary endpoint (progression-free survival) not met according to the results published in the investigational new drugs

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com